Lilly, Incyte score second PhIII success with baricitinib; Savara cites success for MRSA antibiotic;

@FierceBiotech: Merck KGaA carves into MS R&D after a string of setbacks. Story | Follow @FierceBiotech

@JohnCFierce: $LLY, that wunderkind of drug R&D, delays peglispro after all and Tim Anderson sounds taps. Release | Follow @JohnCFierce

@DamianFierce: Big day for Tularik expats, particularly the ones at Flexus and NGM. Story | Report | Follow @DamianFierce

> Eli Lilly ($LLY) and Incyte ($INCY) said today that baricitinib outscored a placebo in their second Phase III study for rheumatoid arthritis. The study for the oral JAK1/JAK2 inhibitor met its primary endpoint of an improved ACR20 response rate compared to placebo after 12 weeks of treatment. Release

> Austin-based Savara Pharmaceuticals says it gained positive topline results from its Phase II clinical trial of AeroVanc, an inhaled antibiotic for methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis. Release

Medical Device News

@FierceMedDev: J&J readies to rid itself of Cordis--for as much as $2B to Cardinal Health. More | Follow @FierceMedDev

@VarunSaxena2: Reg. standards may be for NGS materials, methods & performance. Specific for each area (oncology, germline mutations etc) #PrecisionMedicine. | Follow @VarunSaxena2

@EmilyWFierce: Bayer feels sting of mixed decision from NICE for Eylea's use in diabetics. Article | Follow @EmilyWFierce

> First adhesive varicose vein treatment wins FDA approval. More

> Advisory panel recommends FDA approval of VertiFlex's spinal implant. Story

Pharma News

@FiercePharma: Brain cancer therapy pioneered in dogs wins NCI grant for human development. More | Follow @FiercePharma

@CarlyHFierce: Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash. Release | Follow @CarlyHFierce

> Bayer reportedly close to diabetes device sale worth up to $2.3B. Story

> New Sanofi chief's €4M signing bonus 'incomprehensible' to French officials. News

Biotech IT News

> AstraZeneca picks Labguru to improve collaborations with academia. More

> FDA puts cloud storage and Google-esque search tools on precision medicine road map. Story

> Big Data digging yields unprecedented road map of the epigenome. Article

> BGI investor: It is the database they are building that will make them formidable. Report

> Transcriptic snags $8.5M to add capabilities at robot-run lab. News

CRO News

> LabCorp seals its $6B deal for Covance. Article

> After a $300M IPO, PRA forecasts a big 2015. More

> Theorem partners up for patient testing. Report

> Parexel stretches out its site network to speed up enrollment. Story

> WuXi borrows $165M to bankroll more M&A. Item

Animal Health News

> Jaguar posts positive trial results on lead prescription drug for dogs. Item

> Patterson misses on sales and earnings but reaffirms fiscal 2015 guidance. Report

> Australia's Integrated Animal Health to open offices in U.S. Story

> Brain cancer therapy pioneered in dogs wins NCI grant for human development. News

> Dogs get pulled into the medical marijuana debate. Article

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.